H.Z. KE ET AL: "BONE ANABOLISM ACHEIVED BY REDUCING SCLEROSTIN BIOAVAILABILITY WITH AN ANTI-sclerostin antibody" 36TH INTERNATIONAL SUN VALLEY WORKSHOP ON SKELETAL TISSUE BIOLOGY, 30 July 2006 (2006-07-30), page 02.08.2006, XP002469781 (B1)

HOLDSWORTH GILL ET AL: "Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 3 AUG 2012, vol. 287, no. 32, 3 August 2012 (2012-08-03), pages 26464-26477, ISSN: 1083-351X (B1)

I. KYOJI: "Physiological function of osteocytes" CLINICAL CALCIUM, vol. 17, no. 10, 1 October 2007 (2007-10-01), pages 1554-1558, XP008088787 (B1)

LEWIECKI E MICHAEL: "Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, UK, vol. 11, no. 1, 1 January 2011 (2011-01-01), pages 117-127, XP009160541, ISSN: 1744-7682, DOI: 10.1517/14712598.2011.540565 (B1)

LINTERN KATHERINE B ET AL: "Characterization of Wise Protein and Its Molecular Mechanism to Interact with both Wnt and BMP Signals", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, no. 34, August 2009 (2009-08), pages 23159-23168, ISSN: 0021-9258 (B1)

WO-A-2006/119062 (B1)

VAN BEZOOIJEN R L ET AL: "BONE MORPHOGENETIC PROTEINS AND THEIR ANTAGONISTS: THE SCLEROSTIN PARADIGM" JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, KURTIS, MILAN, IT, vol. 28, no. 8, 2005, pages 15-17, XP008078167 ISSN: 0391-4097 (B1)

VEVERKA VACLAV ET AL: "Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 284, no. 16, 17 April 2009 (2009-04-17), pages 10890-10900, XP002594504, ISSN: 0021-9258, DOI: 10.1074/JBC.M807994200 [retrieved on 2009-02-10] (B1)

WARMINGTON K ET AL: "SCIEROSTIN ANTAGONISM IN ADULT RODENTS, VIA MONOCLONAL ANTIBODY MEDIATED BLOCKADE, INCREASES BONE MINERAL DENSITY AND IMPLICATES SCLEROSTIN AS A KEY REGULATOR OF BONE MASS DURING ADULTHOOD" JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 19, 5 October 2004 (2004-10-05), pages S56-S57,ABSTRA, XP009072609 ISSN: 0884-0431 (B1)

WARMINGTON K ET AL: "SCLEROSTIN MONOCLONAL ANTIBODY TREATMENT OF OSTEOPOROTIC RATS COMPLETELY REVERSES ONE YEAR OF OVARIECTOMY-INDUCED SYSTEMIC BONE LOSS" JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 20, no. 9, 25 September 2005 (2005-09-25), pages S22-PRES1082, XP008078248 ISSN: 0884-0431 (B1)

OMINSKY M S ET AL: "SCLEROSTIN MONOCLONAL ANTIBODY TREATMENT INCREASES BONE STRENGTH IN AGED OSTEOPENIC OVARIECTOMIZED RATS" JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 21, no. 1, 18 September 2006 (2006-09-18), page S44PRES1161, XP008078247 ISSN: 0884-0431 (B1)